PROCYTOX 1000 MG
CYCLOPHOSPHAMIDE : 1000 MG · DIN 02241799 · BAXTER CORPORATION
Health Canada status: MARKETED
What is PROCYTOX?
PROCYTOX 1000 MG contains CYCLOPHOSPHAMIDE : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02241799, held by BAXTER CORPORATION, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 18-Nov-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROCYTOX used for?
Malignant lymphomas (Hodgkin's, NHL), multiple myeloma, leukemias (CLL, CML, AML, ALL), mycosis fungoides, neuroblastoma, adenocarcinoma of the breast, retinoblastoma, and lung neoplasms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PROCYTOX called?
Also recorded in Canada as: cyclophosphamide 500 MG/ML Injectable Solution [Frindovyx] (US), cyclophosphamide 25 MG Oral Capsule (US), cyclophosphamide 50 MG Oral Capsule (US), cyclophosphamide 500 MG Injection (US), cyclophosphamide 1000 MG Injection (US), cyclophosphamide 2000 MG Injection (US), cyclophosphamide 25 MG Oral Tablet (US), cyclophosphamide 50 MG Oral Tablet (US), cyclophosphamide 200 MG/ML Injectable Solution (US), 5 ML cyclophosphamide 200 MG/ML Injection (US), 2.5 ML cyclophosphamide 200 MG/ML Injection (US), 2 ML cyclophosphamide 500 MG/ML Injection (US), 4 ML cyclophosphamide 500 MG/ML Injection (US), 1 ML cyclophosphamide 500 MG/ML Injection (US), cyclophosphamide 100 MG/ML Injectable Solution (US).
The same molecule, CYCLOPHOSPHAMIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Endoxan | Latin | Australia, South Africa |
| Cyclophosphamide (NorthStar, USA) | Latin | Australia |
| Cyclophosphamide (Sagent, USA) | Latin | Australia |
| CYCLOPHOSPHAMIDE-REACH | Latin | Australia |
| Cyclonex | Latin | Australia |
| ENDOXAN SUGAR COATED TABLET | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241799 |
|---|---|
| Brand name | PROCYTOX |
| Generic / active ingredient | CYCLOPHOSPHAMIDE : 1000 MG |
| Manufacturer | BAXTER CORPORATION |
| Strength | 1000 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01AA01 CYCLOPHOSPHAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Nov-2003 |
| Original market date | 2003-11-18 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241799 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241799 |
| Brand name | PROCYTOX |
| Active ingredient / INN | CYCLOPHOSPHAMIDE : 1000 MG |
| ATC code | L01AA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BAXTER CORPORATION |
How is it administered?
Administered orally or intravenously. Dosage must be individualized based on clinical/hematologic response and tolerance. Strong hydration and frequent voiding are essential to reduce urotoxicity.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text summary (refer to full Storage and Stability section 46).
How is it supplied?
Tablets: 25 mg, 50 mg; Injection: 200 mg, 500 mg, 1000 mg, 2000 mg vials.
Which pack is which?
| Strength on the label | 1000 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | Tablets: 25 mg, 50 mg; Injection: 200 mg, 500 mg, 1000 mg, 2000 mg vials. |
| Storage | Not explicitly detailed in provided text summary (refer to full Storage and Stability section 46). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; urinary outflow obstruction; severe myelosuppression, renal or hepatic impairment; active infection (especially varicella zoster); severe immunosuppression.
Warnings and precautions
Secondary malignancies; severe myelosuppression; acute cardiac and pulmonary toxicity; urotoxicity (hemorrhagic cystitis); hepatotoxicity (VOLD); anaphylaxis; interferes with wound healing.
Is CYCLOPHOSPHAMIDE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by ANDONE PHARMACEUTICAL INC (Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTION USP" aria-label="Anticipated Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTI), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01AA01 CYCLOPHOSPHAMIDE. 12 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02560216 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | Injection | STERIMAX INC | MARKETED | DIN 02547686 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | DIN 02546736 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02560224 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02547694 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | DIN 02546744 |
| PROCYTOX | 200 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241797 |
| PROCYTOX | 2000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241800 |
| PROCYTOX | 500 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241798 |
| PROCYTOX TAB 25MG | 25 MG | TABLET | BAXTER CORPORATION | MARKETED | DIN 02241795 |
Who else supplies CYCLOPHOSPHAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CYCLOPHOSPHAMIDE appears in 28 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CYCLOPHOSPHAMIDE cost around the world?
CYCLOPHOSPHAMIDE is listed on 6 national price registers Nexara tracks, across 38 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 5 | 9 | 08 Sep 2026 |
| Saudi Arabia | public | 7 | 7 | 01 Sep 2026 |
| Morocco | PPV (public price) | 6 | 6 | 05 Sep 2026 |
| United States | acquisition | 2 | 6 | 03 Sep 2026 |
| South Africa | single exit price | 2 | 6 | 01 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.